6
Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. Yu SCH, Chan SL, Lee KF, Hui JWY, Hui EP, Chu CM,et al. Radiology. 2018 Apr;287(1):340-348. doi: 10.1148/radiol.2017170154. Epub 2017 Dec 22. PMID: 29272212.
7
Long-Term Evolutionary Change in the Lumen of Intracranial Atherosclerotic Stenosis Following Angioplasty and Stenting. Yu SCH, Lau TWW, Wong SSM, Lee KT, Wong LKS, Leung TWH. Oper Neurosurg (Hagerstown). 2018 Feb 1;14(2):128-138. doi: 10.1093/ons/opx097. PMID: 28637237.
8
Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. Yu SC, Hui EP, Tang P, Chan SK, Chu CC, Hui JW, et al. J Vasc Interv Radiol. 2016 May;27(5):639-49. doi: 10.1016/j.jvir.2015.11.032. Epub 2016 Jan 20. PMID: 26803574.
9
SIRT-Y90 followed by gemcitabine plus cisplatin for Intra-hepatic cholangiocarcinoma: a phase II study. Chan SL, Tai D, Li L, Yu SCH, Ng D, Choo SP. Ann Oncol. 2015; 26 (Supplement 7): vii106-vii151. doi:10.1093/annonc/mdv472.72.
10
Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, et al. HPB (Oxford). 2014 Apr;16(4):366-72. doi: 10.1111/hpb.12146. Epub 2013 Aug 26. PMID: 23980880; PMCID: PMC3967889.